J
Closed
Joint targeting of transcription and translation for medulloblastoma
Research funding for relapsed medulloblastoma
Last Update: May 13, 2026
Funding available
$ 100,000
Timeline
- Receipt of requests is now closed
Location
Canada
Overview
This program supports research on relapsed medulloblastoma in children. It provides $100,000 over 3 years for work exploring omacetaxine and related agents as a potential path toward pediatric clinical trials.
/100
Opportunity Score
Moderate potential, but conditions must align.
At a glance
Funding available
Financing goals
- Conduct research and development activities
Eligible Funding
- Maximum amount : 100,000 $
Timeline
- Receipt of requests is now closed
Eligible candidates
Eligible Industries
- Health care and social assistance
Location
- Canada
Legal structures
- Public or Parapublic institution
Annual revenue
- All revenue ranges
Organisation size
- All organization sizes
Audience
- Canadians
Next Steps
1
Determine your project
2
Validate your eligibility
Activities funded
- Research on relapsed medulloblastoma in children.
- Study of omacetaxine alone and with similar agents.
- Work aimed at advancing a treatment into pediatric clinical trials.
Eligibility
Who is eligible?
- University of Michigan.
Eligible geographic areas
- University of Michigan, United States.
Contacts
Frequently Asked Questions about the Joint targeting of transcription and translation for medulloblastoma Program
Here are answers to the most common questions about the Joint targeting of transcription and translation for medulloblastoma. This section explains what the program is, how much funding is available, eligibility requirements, application deadlines, and other important details to help you determine if this grant is right for your business.
What is the Joint targeting of transcription and translation for medulloblastoma?
This program supports research on relapsed medulloblastoma in children. It provides $100,000 over 3 years for work exploring omacetaxine and related agents as a potential path toward pediatric clinical trials.
How much funding can be received?
Joint targeting of transcription and translation for medulloblastoma Funds up to $100,000 of admissible expenses.
What expenses are eligible under Joint targeting of transcription and translation for medulloblastoma?
Research on relapsed medulloblastoma in children.
Study of omacetaxine alone and with similar agents.
Work aimed at advancing a treatment into pediatric clinical trials.
Who can I contact for more information about the Joint targeting of transcription and translation for medulloblastoma?
You can contact Cannonball Sport & Education Foundation by email at none or by phone at none.
Where is the Joint targeting of transcription and translation for medulloblastoma available?
The Joint targeting of transcription and translation for medulloblastoma program is available across Canada.
Is the Joint targeting of transcription and translation for medulloblastoma a grant, loan, or tax credit?
Joint targeting of transcription and translation for medulloblastoma is a Grant and Funding
Who are the financial supporters of the Joint targeting of transcription and translation for medulloblastoma?
Joint targeting of transcription and translation for medulloblastoma is funded by Cannonball Sport & Education Foundation